Merck relaunches customer collaboration centers with new concept and M Lab name
Merck's M Lab Collaboration Centers offer customers the opportunity to explore, learn and collaborate at the company's global network of sites around the world, solving the challenges they face every day.
Enables explorations of new technologies and solutions to address development and manufacturing challenges.
Merck is relaunching its global network of customer collaboration centers, providing customers a shared, exploratory environment with scientists and engineers working to solve their toughest biomanufacturing challenges, helping accelerate development of new therapies.
Formerly known as biomanufacturing science training centers, the new state-of-the-art M Lab concept will include a simulated manufacturing environment that provides customers a setting that fosters education and full end-to-end development support. The centers are created especially for customer collaboration in which problem solving for processing issues take place. Customers participate in product demonstrations, hands-on training and experiments, as well as apply best practices and new approaches to develop, optimize and scale-up processes and simplify global technology transfer.
"We are the only company that offers full end-to-end process training, and we do it side-by-side with our customers, working together to solve critical challenges," said Udit Batra, Member of the Merck Executive Board and CEO, Life Science.
Now reimagined and reengineered as M Lab Collaboration Centers, Merck has taken its industry-leading concept to the next level by creating unique and inspiring settings where customers can explore new ways to increase productivity and improve processes in close collaboration Merck's team of experts.
"These centers have been an important resource for our customers and the biopharma industry for more than two decades and will continue to be important as we grow," Batra added.
Merck unveiled its first remodeled center in Tokyo, Japan on 29 June 2016. The network, established in 1995, will also include locations in Brazil, China, France, India, Singapore, South Korea and the United States. Formal relaunch of these centers will take place throughout the remainder of 2016 and 2017 with openings of the new M Lab concept in France, India, China, South Korea and the US.
Each center will welcome customers, collaborators from government, academia, regulatory bodies and industry associations, offering application best practices and knowledge sharing tailored to address the specific needs of the local biomanufacturing industry. Customers will have access to sizing and simulation tools and methodologies as well as analytical and modeling support. Hands-on and classroom-style training sessions and education programs are also provided.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...